Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
On Friday, the fledgling field of psychedelic medicine suffered a major setback. The FDA declined to approve MDMA-assisted therapy for PTSD, instead asking the drugmaker Lykos Therapeutics to conduct ...
If you are a therapy patient or care for someone who is, the possibility of taking prescribed medications for depression, anxiety, insomnia, mood swings, ADHD, OCD, psychotic symptoms, drug cravings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results